Evidence map›Paper›PMID 39702778›Full record

ArticleCommunications chemistry2024

Ortho-functionalized pyridinyl-tetrazines break the inverse correlation between click reactivity and cleavage yields in click-to-release chemistry.

Ron M Versteegen, Raffaella Rossin, Ivo A W Filot, Freek J M Hoeben, Arthur H A M van Onzen, Henk M Janssen, Marc S Robillard

Erratum issuedAbstract read
In one paragraph

Article in Communications chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Click-to-Release Reactions for Tertiary Amines and Pyridines.Journal of the American Chemical Society · 2026
    Article
  4. Article
  5. Review
  6. Covalent chemical probes.Communications chemistry · 2025
    Article
  7. Scission-Enhanced Molecular Imaging (SEMI).Bioconjugate chemistry · 2024
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Ron M VersteegenSyMO-Chem B.V., Den Dolech 2, 5612 AZ, Eindhoven, The Netherlands.
Raffaella RossinTagworks Pharmaceuticals, Toernooiveld 1, 6525 ED, Nijmegen, The Netherlands.
Ivo A W FilotEindhoven University of Technology, Den Dolech 2, 5612 AZ, Eindhoven, The Netherlands.ORCID http://orcid.org/0000-0003-1403-8379
Freek J M HoebenSyMO-Chem B.V., Den Dolech 2, 5612 AZ, Eindhoven, The Netherlands.ORCID http://orcid.org/0009-0007-9001-7402
Arthur H A M van OnzenTagworks Pharmaceuticals, Toernooiveld 1, 6525 ED, Nijmegen, The Netherlands.
Henk M JanssenSyMO-Chem B.V., Den Dolech 2, 5612 AZ, Eindhoven, The Netherlands.ORCID http://orcid.org/0000-0002-2588-846X
Marc S RobillardTagworks Pharmaceuticals, Toernooiveld 1, 6525 ED, Nijmegen, The Netherlands. marc.robillard@tagworkspharma.com.ORCID http://orcid.org/0000-0002-3690-2087

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The bioorthogonal tetrazine-triggered cleavage of trans-cyclooctene(TCO)-linked payloads has strong potential for widespread use in drug delivery and in particular in click-cleavable antibody-drug conjugates (ADCs). However, clinical translation is hampered by an inverse correlation between click reactivity and payload release yield, requiring high doses of less reactive tetrazines to drive in vivo TCO reactions and payload release to completion. Herein we report that the cause for the low release when using the highly reactive bis-(2-pyridinyl)-tetrazine is the stability of the initially formed 4,5-dihydropyridazine product, precluding tautomerization to the releasing 1,4-dihydropyridazine tautomer. We demonstrate that efficient tautomerization and payload elimination can be achieved by ortho-substituting bis-pyridinyl-tetrazines with hydrogen-bonding hydroxyl or amido groups, achieving a.o. release yields of 96% with 18-fold more reactive tetrazines. Applied to on-tumor activation of a click-cleavable ADC in mice, these tetrazines afforded near-quantitative ADC conversion at a ca. 10- to 20-fold lower dose than what was previously needed, resulting in a strong therapeutic response.

Identifiers

PMID39702778
PMCPMC11659415

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.